Journal article
Fc-g receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer
G Liu, D Tu, M Lewis, D Cheng, LA Sullivan, Z Chen, E Morgen, J Simes, TJ Price, NC Tebbutt, JD Shapiro, GM Jeffery, JD Mellor, T Mikeska, S Virk, LE Shepherd, DJ Jonker, CJ O'Callaghan, JR Zalcberg, CS Karapetis Show all
Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2016
Abstract
Purpose: Two germline Fc-g receptor (FCGR) polymorphisms, rs1801274 [FCGR2A;His(H)131Arg(R)] and rs396991 [FCGR3A; Phe(F)158Val(V)] produce altered proteins through amino acid substitutions; both are reported to be associated with cetuximabrelated outcomes. We performed a validation of these polymorphisms in NCIC CTG CO.17, a randomized trial of cetuximab monotherapy in refractory, metastatic colorectal cancer expressing EGFR. Experimental Design: DNA extracted from formalin-fixed paraffin-embedded tissue was genotyped. In addition to log-rank tests, Cox proportional hazard models assessed their relationships with overall (OS) and progression-free survival (PFS), adjusting for clinically imp..
View full abstractGrants
Funding Acknowledgements
This research was supported by an OICR High Impact Clinical Trial Small Project Grant and by an unrestricted grant from Transgenomic, Inc. G. Liu was supported by the Alan B. Brown Chair in Molecular Genomics and the Cancer Care Ontario Chair in Experimental Therapeutics and Population Studies, E. Morgen was supported by a CIHR Banting and Best Canada Graduate Scholarship, and J.D. Mellor was supported by a grant from the Peter MacCallum Cancer Centre Research Foundation. This work was also supported by the NCIC Clinical Trials Group Tumour Tissue Data Repository (TTDR). The NCIC CTG TTDR is a member of the Canadian Tumour Repository Network.